

Special Issue

Autoimmune and Inflammatory Disorders: From Pathogenesis to Therapeutic Targeting

Message from the Guest Editor

This Special Issue aims to highlight recent advances in understanding immune dysregulation and its therapeutic implications. We welcome original research and reviews focusing on the molecular mechanisms underlying autoimmune and chronic inflammatory diseases. Submissions exploring how inflammasome activation contributes to the pathogenesis of sepsis, chronic inflammation, and autoimmune disorders are of particular interest. We encourage studies proposing strategies to modulate inflammasome activity, such as small-molecule inhibitors, genetic approaches, or upstream signaling modulators, to restore immune balance and ameliorate disease progression. In addition, we invite contributions that investigate the microbiota-immune axis, including how microbial communities, metabolites, or microbe–host interactions regulate immune responses and impact disease development or resolution. Overall, this Special Issue seeks to bridge basic mechanistic insights with translational potential, providing a platform for discoveries that advance our understanding of immune-mediated diseases and support the development of novel therapeutic interventions targeting inflammatory and autoimmune pathways.

Guest Editor

Dr. Yu-Wei Chang

Department of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402306, Taiwan

Deadline for manuscript submissions

31 March 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/250256

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).